Curevo Vaccine has closed a $110 million Series B funding round, led by Medicxi, to further develop its shingles vaccine, amezosvatein. The investment will support the expansion of their Phase 2 program to include more participants over age 70.
Amount Raised
$110 Million
Round Type
Series B
SeattleBiotechnologyHealthcareMobileSportsPlatformsInvestors
Description
Curevo Vaccine has announced the closing of a $110 million Series B funding round aimed at advancing their shingles vaccine, amezosvatein. The round was led by new investor Medicxi and included participation from several other investment firms. This funding will allow Curevo to extend their Phase 2 program into a larger participant count to finalize dose selection for their upcoming Phase 3 program. Additionally, Moncef Slaoui will join Curevo as Board Chair to further guide the company's strategic initiatives.
Quick answer
Curevo raised $110 Million in a Series B round, dated March 17, 2025. Investors: Gc Biopharma, Orbimed, HBM Healthcare Investments, Sanofi Ventures, RA Capital Management, Janus Henderson Investors, Adjuvant Capital and Medicxi. Curevo is based in Seattle, Washington, United States.
- How much did Curevo raise?
- Curevo raised $110 Million in a Series B round on March 17, 2025.
- Who invested in Curevo?
- Gc Biopharma, Orbimed, HBM Healthcare Investments, Sanofi Ventures, RA Capital Management, Janus Henderson Investors, Adjuvant Capital and Medicxi are named as investors in this round.
- What does Curevo do?
- Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility.
- Where is Curevo based and how big is it?
- Curevo is based in Seattle, Washington, United States. Fundz records about 44 employees.
- Who are the decision-makers at Curevo?
- Fundz holds 2 contacts at Curevo, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Mobile around the same time
Companies in the same sectors as Curevo that raised within 45 days of this round, from Fundz verified event records.
- Trethera raised $250K on April 29, 2025.
- Gestalt Diagnostics raised $7.5M (Series A) on April 28, 2025.
- Araceli Biosciences raised $11M (Seed) on April 24, 2025.
- Ensysce Biosciences raised $2.2M (Seed) on April 23, 2025.
- Retension Pharmaceuticals raised $12M on April 22, 2025.
- Alessa Therapeutics raised $25M on April 18, 2025.
Who to call at Curevo, and when
A new round usually means Curevo is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Curevo raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Curevo, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Curevo. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curevo raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCurevo raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.